Drawing based on the label description. No photo yet.
“15 mg tablets are pale yellow, round, flat-faced, speckled, unscored tablets debossed with M on one side of the tablet and LP1 on the other side”
M LP1 pill
Pill with imprint M LP1 is yellow, round, 11 mm and has been identified as Lansoprazole 15 mg. It is used for acid reflux (GERD), ulcers and stomach ulcers. It is supplied by Mylan Pharmaceuticals Inc.
Lansoprazole 15 mg
- Imprint
- M LP1
- Strength
- 15 mg
- Used for
- Acid reflux (GERD), ulcers and stomach ulcers
- Color
- Yellow
- Shape
- Round
- Size
- 11 mm
- Score
- No score line
- Form
- Tablet, orally disintegrating, delayed release
- Manufacturer
- Mylan Pharmaceuticals Inc
- Drug class
- Acid reducer (proton pump inhibitor)
- NDC
- 0378-6981, 0378-6981-32, 0378-6981-85, 0378-6981-88
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Lansoprazole used for?
Lansoprazole is used for acid reflux (GERD), ulcers, stomach ulcers and H. pylori infection.
- Medicine type
- Acid reducer (proton pump inhibitor)
Official uses from the US prescribing label
Treatment of Active Duodenal Ulcer
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer.
Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence
Triple Therapy: Lansoprazole delayed-release orally disintegrating tablets /amoxicillin/clarithromycin
Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Please refer to the full prescribing information for amoxicillin and clarithromycin.
Dual Therapy: Lansoprazole delayed-release orally disintegrating tablets/amoxicillin
Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, Microbiology section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Please refer to the full prescribing information for amoxicillin.
Maintenance of Healed Duodenal Ulcers
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months.
Treatment of Active Benign Gastric Ulcer
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer.
Healing of NSAID-Associated Gastric Ulcer
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond eight weeks.
Risk Reduction of NSAID-Associated Gastric Ulcer
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks.
Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)
Lansoprazole delayed-release orally disintegrating tablets are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for the treatment of heartburn and other symptoms associated with GERD.
Treatment of Erosive Esophagitis (EE)
Lansoprazole delayed-release orally disintegrating tablets are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for healing and symptom relief of all grades of EE. For adults who do not heal with lansoprazole delayed-release orally disintegrating tablets for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis an additional eight week course of lansoprazole delayed-release orally disintegrating tablets may be considered.
Maintenance of Healing of EE
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults to maintain healing of EE. Controlled studies did not extend beyond 12 months.
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)
Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
From the FDA-approved label on DailyMed (published Sep 02, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows M and the other side shows LP1.
- It is yellow, round, 11 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Lansoprazole
Inactive: Aspartame, Citric Acid Monohydrate, Crospovidone, Hydroxypropyl Cellulose, Unspecified, Magnesium Carbonate, Magnesium Stearate, Mannitol, Methacrylic Acid and Ethyl Acrylate Copolymer, Microcrystalline Cellulose, Polyethylene Glycol, Unspecified, Polysorbate 80, Sodium Bicarbonate, Sodium Hydroxide, Sodium Lauryl Sulfate, Sodium Starch Glycolate Type A Potato, Talc, Triethyl Citrate, Ferric Oxide Yellow, Starch, Corn, Sucrose
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
AA 44
Azathioprine 75 mg
Yellow, round, 10 mm
Used for multiple sclerosis and rheumatoid arthritis
-
PLIVA 471
Propranolol Hydrochloride 80 mg
Yellow, round, 10 mm
Used for high blood pressure and heart failure
-
224 G breakline
Lithium Carbonate 450 mg
Yellow, round, 11 mm
Used for depression and PTSD
-
AA 45
Azathioprine 100 mg
Yellow, round, 11 mm
Used for multiple sclerosis and rheumatoid arthritis
-
C C 57
Clozapine 100 mg
Yellow, round, 10 mm
Used for bipolar disorder and schizophrenia
-
T 50
Phenytoin 50 mg
Yellow, round, 11 mm
Used for tonic-clonic seizures and long-lasting seizures
Other Lansoprazole pills
-
RDY LAN
Lansoprazole 15 mg
Green & pink, capsule, 16 mm
Used for acid reflux (GERD) and ulcers
-
RDY 399
Lansoprazole 30 mg
Black & pink, capsule, 19 mm
Used for acid reflux (GERD) and ulcers
- TAP PREVACID 15 Lansoprazole 15 mg Green & pink, capsule, 16 mm Used for acid reflux (GERD) and ulcers
- TAP PREVACID 15 Lansoprazole 15 mg Green, capsule, 16 mm Used for acid reflux (GERD) and ulcers
- 15 Lansoprazole 15 mg White, round, 9 mm Used for acid reflux (GERD) and ulcers
- 93 7350 Lansoprazole 15 mg Blue & white, capsule, 16 mm Used for acid reflux (GERD) and ulcers
- W 669 Lansoprazole 15 mg Green & pink, capsule, 16 mm Used for acid reflux (GERD) and ulcers
- RDY 398 Lansoprazole 15 mg Green & pink, capsule, 16 mm Used for acid reflux (GERD) and ulcers